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Aims: Transcatheter aortic valve implantation (TAVI) is an increasingly common intervention 
for patients with aortic stenosis deemed high-risk for major cardiac surgery, but identifying 
those who will benefit can be challenging. Frailty reflects physiological reserve and may be a 
useful prognostic marker in this population. We performed a systematic review and meta-
analysis of the association between frailty and outcomes after TAVI. 
Methods and Results: Five databases were searched between January 2000 and May 2015. 
From 2,623 articles screened, 54 were assessed for eligibility. Ten cohort studies (n=4,592) 
met the inclusion criteria of reporting a measure of frailty with early (≤30 days) or late (>30 
days) mortality and procedural complications following TAVI as defined by the Vascular 
Academic Research Consortium (VARC).  
Frailty was associated with increased early mortality in four studies (n=1,900) (HR 
2.35, 95% CI 1.78-3.09, p<0.001), and increased late mortality in seven studies (n=3159) (HR 
1.63, 95% CI 1.34-1.97, p<0.001). Objective frailty tools identified an even higher risk group 
for late mortality (HR 2.63, 95% CI 1.87-3.70, p<0.001). Frail individuals undergoing TAVI 
have a mortality rate of 34 deaths per 100 patient years, compared to 19 deaths per 100 
patient years in non-frail patients. There was limited reporting of VARC procedural outcomes 
in relation to frailty, preventing meta-analysis. 
Conclusions: Frailty assessment in an already vulnerable TAVI population identifies 
individuals at even greater risk of poor outcomes. Use of objective frailty tools may inform 
patient selection, but this requires further assessment in large prospective registries.  
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Aortic stenosis is the most common valvular disease in the Western World, affecting 1 in 8 
individuals over the age of 75 years. The incidence of functionally important disease is rising 
in line with the ageing population, providing challenges for conventional valve replacement 
surgery.1 Patients over 80 years old undergoing elective cardiac surgery have more operative 
complications and a 10 percent mortality rate at 30 days; therefore decisions around 
intervention in older patients are complex.2 Transcatheter Aortic Valve Implantation (TAVI) 
has become a widespread and viable alternative for patients considered high-risk for 
conventional surgery. Population modelling suggests in excess of 91,000 people fall into this 
category across North America each year.1 The Society of Thoracic Surgeons (STS)3 and 
EuroSCORE4 tools are often used to guide treatment based on the predicted risk of poor 
outcomes, but these scoring systems have not been designed or formally tested in TAVI 
populations.  The application of such scores in elderly patients suitable for conventional 
surgery has also been questioned.5,6 Many believe that a holistic approach through frailty 
assessment may improve the decision making process.  
Frailty is a multimodal concept describing loss of strength, endurance and 
physiological reserve across multiple systems that increases vulnerability for developing 
dependency or death.7 It becomes more common with age, but is a very distinct concept of 
biological rather than chronological years; indeed the majority of individuals over 85 years 
old are not frail. Common models focus on the development of a phenotype or the gradual 
accumulation of deficits over time, but there is no clear consensus on the best form of 
measurement.7-9 Within non-cardiac surgical cohorts, frailty is predictive of mortality, post-
operative complications and institutionalisation.10-13 It is plausible that such measures 
applied to high-risk patients undergoing TAVI may improve the discrimination of current risk 









assessment tools for important patient outcomes. In this systematic review, we evaluate the 




We conducted a systematic literature review of Medline, EMBASE and CINAHL databases 
between 1st January 2000 and 1st June 2015 using the key search terms of frailty (and its 
synonyms) and TAVI (and its synonyms) (Supplementary Appendix). Reference and forward 
citation searching via the Web of Science (Thomson Reuters) was performed on papers 
meeting the criteria for inclusion. Hand-searching using the primary search terms was 
performed within the three most commonly identified journals from the initial search. This 
was repeated using the Google Scholar search engine.  
 
Eligibility criteria 
We included any primary peer-reviewed paper where a measure of frailty was defined by 
the authors prior to TAVI, and where this was related to at least one of the predefined post-
TAVI outcomes. No other assessments were adjudicated to represent frailty unless 
stipulated as a determinant of frailty by the authors of a study. No restrictions were placed 
on the age of study participants, specific vascular route or operator technique by which TAVI 
was performed. Results in all languages were considered, using translation services where 
required to adjudicate eligibility.  
The primary outcome was all-cause mortality after TAVI, either reported in the short 
(≤30 days) or long term (>30 days). Secondary outcomes comprised procedural 
complications as defined by the Valve Academic Research Consortium (VARC) standardized 









endpoint definitions. These include cardiovascular mortality, myocardial infarction, major 
stroke, bleeding, acute kidney injury requiring dialysis and numerous other vascular 
complications.14 Any measures of functional capacity or patient independence after TAVI 
were sought as secondary outcomes where the relationship to a pre-TAVI frailty measure 
was presented. Review articles and non-peer reviewed material (such as conference 
proceedings and poster abstracts) were excluded.  
 
Data extraction 
All extracted abstracts and full-text articles meeting the inclusion criteria were assessed 
between three researchers (AA, AV and CH), such that two people independently reviewed 
each submission. Disagreements were resolved by consensus including the third reviewer. 
For each study meeting the inclusion criteria, a standardised data extraction form was 
developed to record study design, TAVI population demographics, assessed risk of the 
population (STS and EuroSCORE), specific frailty measure, length to follow-up and any data 
related to the primary and/or secondary outcomes. Where the relationship between frailty 
and outcome was qualitatively but not quantitatively expressed, primary authors were 
contacted in an attempt to gain additional primary data. Where the same study appeared to 
be reported across more than one article, only the most complete submission was included, 
with the aim of maximising the volume of frailty data included.  
 
Quality and bias assessment 
No validated quality assessment tool has been widely established to assess observational 
studies that are not designed to directly compare two groups. The Newcastle-Ottawa Scale 
was used to provide a structured assessment of sample selection (4 points), comparability (2 









points) and outcomes (3 points).15 This gives a maximum score of 9 points. Studies were 
independently assessed by two reviewers and disagreement resolved by consensus: ≥7 
points considered high quality for frailty reporting, <7 moderate or low quality. Publication 
bias was assessed in the primary endpoint with the greatest number of studies by creating a 
funnel plot and using Egger’s regression test.16 We then corrected for asymmetry using the 
trim and fill method to determine an adjusted effect size.17  
 
Data synthesis and analysis 
All included studies were observational cohorts with respect to frailty. Meta-analysis was 
performed when at least three studies reported a comparable endpoint to generate a meta-
estimate. Given the wide number of frailty tools available, significant heterogeneity was 
expected across the studies and therefore a random-effects model (maximum likelihood 
approach) was chosen to calculate summary effect estimates.18 Statistical analysis was 
performed using the metafor statistical package within R version 3.1.3 (http://www.r-
project.org) and GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA). A 
value of p<0.05 was considered statistically significant. 
 
Results 
Search results and patient characteristics 
We identified 2,623 abstracts from our initial search, resulting in 54 articles for full-text 
review to assess eligibility. Ten studies from Europe and North America met the full inclusion 
criteria (Figure 1). These comprised 4,592 patients undergoing TAVI in whom a frailty 
measure was made prior to surgery. The mean age was 80 to 86 years, 34% to 53% of 
participants were men, and the STS-predicted 30-day mortality rates where available were 









between 6.3% and 16.6%. In those studies detailing the access route chosen for TAVI, the 
femoral approach was the most common, although this ranged from 47% to 100% of cases. 
The proportion of TAVI patients identified as frail varied greatly across the included studies, 
from 5% to 83% (Table 1). 
 
Definitions of frailty 
Frailty was identified by authors as either subjective (four studies) or objective (six studies). 
Subjective frailty was based on the judgement of a clinical team without reporting use of a 
specific tool. Objective frailty was determined by use of a tool specifically with the purpose 
of defining frailty, such as activity of daily living assessments, comprehensive geriatric 
assessment and frailty indices. With the exception of one small study of 30 patients by 
Kamga et al19, frailty data was available as a dichotomised variable when related to 
outcomes, even where it had been measured on a continuous scale. 
 
Frailty and mortality 
Four studies (n=1,900) reported frailty (using objective measures) and early (≤30 days) 
mortality after TAVI (Table 2 and Figure 2), identifying greater than doubling of the risk of 
early death amongst patients identified as frail (HR 2.35, 95% CI 1.78-3.09, p<0.001). All 
papers reported unadjusted univariate analyses for the association between frailty and 
mortality. There was no significant heterogeneity between studies (I2=0%, p=0.33). 
Seven studies (n=3,159) quantified the relationship between frailty and late mortality 
>30 days after TAVI, with every study completing at least one year of follow-up (Table 3 and 
Figure 2). All reported an increased risk of death amongst frail patients, with an overall 
effect size of HR 1.63 (95% CI 1.34-1.97, p<0.001). The was only marginally increased by 









restricting analysis to studies undertaking adjustment for potential confounders (5 studies, 
HR 1.85, 95% CI 1.34-2.55, p<0.001) or including only studies of higher quality for frailty 
reporting (4 studies, HR 1.79, 95% CI 1.28-2.50, p<0.001). There was moderate 
heterogeneity (I2=66%, p=0.01), which was reduced by performing a sensitivity analysis by 
the type of frailty measure used (Figure 3 and Supplementary Figure 1). The mortality risk 
for frail patients was greater amongst those studies using an objective measure (HR 2.63, 
95% CI 1.87-3.70, p<0.001) rather than subjective assessment (HR 1.42, 95% CI 1.28-1.59, 
p<0.001). 
Five studies provided the absolute number of deaths by frailty status allowing 
combined incidence estimations. This calculation totalled 3629 TAVI patients (24.6% frail) 
followed for the equivalent of 2717 patient years. Amongst those with frailty, 34 deaths/100 
patient years were observed, against 19 deaths/100 patient years in non-frail individuals 
(Table 4). Two studies could not be included in the meta-analysis due to frailty being 
reported as a continuous variable (Kamga et al19), or because only a composite end point of 
MACCE (major adverse cardiovascular or cerebrovascular event) rather than all-cause 
mortality was reported (Ewe et al20). However, both studies did report significant 
associations of frailty with poorer outcomes including late mortality. 
 
Frailty and VARC outcomes 
There was wide variation in the reporting of secondary outcomes across the included 
studies, with only three studies reporting comparable outcomes in relation to frailty. Meta-
analysis of these endpoints was therefore not possible. VARC outcome measures ≤30 days 
after TAVI were reported in relation to frailty status in only two of the included studies, 
totalling 544 patients (Table 2). Both used objective tools, and reported increased effect 









estimates for the risk of major bleeding and renal failure requiring dialysis in frail patients, 
but only the latter complication reached significance in the paper by Puls et al (OR 2.23, 95% 
CI 1.12-4.47, p=0.02). Both studies reported no increase in the risk of stroke amongst frail 
individuals after TAVI.  
 
Quality and risk of bias  
Six studies met our frailty-defined criteria for high quality (Newcastle-Ottowa scale score ≥ 
7) and four were considered moderate or low in quality (Supplementary Table S1). No study 
scored maximum points. All those considered of lower quality did not include adjustment for 
potential confounders of the relationship between frailty and outcomes. Publication bias 
was observed amongst the seven studies reporting late mortality (Egger’s test for 
asymmetry p=0.02). Adjustment by the trim and fill method (see Supplementary Figure S2 
funnel plot) had no effect on the size estimate, which remained statistically significant (HR 
1.59, 95% CI 1.33-1.90, p<0.001 vs HR 1.63, 95% CI 1.34-1.97, p<0.001 before adjustment). 
 
Discussion 
In this systematic review and meta-analysis we explored the relationship between pre-
procedure frailty and outcomes after TAVI in 10 studies from Europe and North America 
comprising 4,592 patients. We have made several important observations. First, the 
measurement of frailty detects a population at double the risk of both early and late 
mortality after TAVI. Second, using objective measures of frailty appears to identify an even 
more vulnerable group than ‘end-of-the-bed’ subjective assessment. However, it is worth 
acknowledging that such subjective frailty assessment still provides important discrimination 









of risk within a population already considered at ‘high-risk’ for conventional surgery. Third, 
VARC complication rates in relation to frailty status are not well reported, with only very 
limited data to suggest increased risk of dialysis requirement and bleeding risk in frail 
patients. However, these observations were not suitable for meta-analysis and are subject to 
competing risk bias from the increased early mortality observed amongst those with frailty. 
A recent review by Puri et al has emphasised the potential value of frailty assessment 
in TAVI candidates.21 Through the process of systematic review and meta-analysis, we have 
further clarified the growing body of research in this area and have numerically quantified 
the mortality risk of frailty identified by both objective and subjective measures. Established 
methods for determining those most likely to benefit from TAVI over medical management 
or conventional surgical aortic valve replacement are lacking. The PARTNER randomised 
controlled trial of high-risk severe aortic stenosis patients, demonstrated improved survival 
with TAVI, but 43% of patients had still died within 2 years of intervention compared to 68% 
with standard medical care. The stroke rate of 13.8% in the TAVI cohort was also more than 
double that of medically managed patients,22-25 although rates are falling as procedural 
techniques improve.26 TAVI as an intervention may therefore have population level survival 
benefits over medical management, but the severe aortic stenosis population is 
heterogeneous and individual risk is likely to vary greatly.  
Mortality prediction using traditional risk assessment tools such as the STS mortality 
score and logistic EuroSCORE was commonly reported amongst the reviewed papers. It is 
possible to directly compare these figures to observed early (≤30 days) mortality in six of the 
included studies (Supplementary Table S2). This comparison highlights the poor correlation 
of predictive scores with actual outcomes in this population, which is perhaps unsurprising 
given these tools were developed in younger cohorts excluding TAVI. Others have also 









identified the weakness of existing risk scores.5,6 It is noteworthy that these predictive 
algorithms only provide prognostic estimates for early surgical outcomes, which may not be 
the most important endpoint after TAVI. In such complex older patients approaching the end 
of life, quality of life after intervention may be more important than survival or avoidance of 
procedural complications. A systematic review by Kim et al of function and quality of life 
after TAVI reported mixed patient outcomes, with improvements in physical function 
amongst survivors not matched by changes in psychological and general health measures.27 
Frailty has gained traction within surgical and cardiovascular literature as a potential 
metric for the currently unmeasured risk of older patients undergoing complex 
interventions.10-13 Whilst this may be seen as positive for the holistic care of older patients, 
there is wide variation in definitions and measurement. In this review, the six studies that 
sought to objectively measure frailty each used different tools, varying from functional 
scales to composite scores including nutrition, cognition and mobility. In the absence of trial 
data with randomisation based upon frailty, it is not possible to infer which elements of 
these measures will carry the most prognostic weight. However, it is notable that all the 
tools used included some estimation of participation in activities of daily living. It is possible 
that such measures are particularly sensitive to procedural risk in severe aortic stenosis 
populations, as impairments may reflect established heart failure at the time of 
consideration for TAVI.  
There remains no consensus on the optimum approach to frailty assessment. The 
majority of studies included in this review considered frailty as a dichotomised variable for 
the purpose of outcome analysis. This reflects the phenotypic model of frailty and is perhaps 
attractive as a simple clinical concept.8 However, forcing a continuous variable into a binary 
form limits the consideration of a ‘pre-frail’ status, and may be open to criticism for the 









potentially arbitrary nature of the threshold used to define frailty. Dichotomous phenotypic 
frailty assessment may also suffer from saturation amongst the highest risk populations and 
therefore provide limited discrimination compared to an index of deficits.28 A formal Frailty 
Index, such as that first described by Rockwood et al29, may better reflect the accumulation 
of markers of frailty over time. Three of the included studies do present some outcome data 
per unit change in the chosen frailty index, but given the differences in the structure of these 
scales meta-estimation of a combined effect size was not possible or logical.  
Although the included studies comprise 4,592 patients undergoing TAVI, there are 
even larger published population registries in America, the United Kingdom, France, 
Germany, Italy and Belgium. Unfortunately, there is currently no systematic measurement of 
frailty within any of these cohorts of consecutive patients.30-34 It is likely that these registries 
will be used to produce future TAVI-specific surgical risk assessment tools similar to STS and 
EuroSCORE, and therefore inclusion of frailty measurement would provide a valuable 




Several limitations of our review should be considered. First, there are no studies 
randomised by frailty status, and so it is likely that patient selection in the observational 
cohort studies included in our meta-analysis was already influenced by underlying and 
unmeasured frailty. This is inevitable given the nature of TAVI as a treatment reserved for 
high-risk aortic stenosis patients requiring valve replacement. Whilst this selection bias may 
limit interpretation of frailty measurement in a broader aortic stenosis population, the 
results are representative of real-world TAVI cohorts. Studies evaluating frailty and 









outcomes in patients referred for TAVI, but in whom the procedure was felt too high risk by 
their multidisciplinary team, would be informative but to our knowledge, no such studies 
have been reported. Second, we have only included studies where frailty was defined by the 
researchers. It is possible that other data exist including similar measurements without 
specific use of the term frailty. However, such studies would be less likely to report 
outcomes directly related to these measures without acknowledging the concept of frailty. 
Third, the meta-estimate for early mortality is based on a small number of studies, without 
adjustment for potential confounders. We were limited by the infrequent reporting of 
standardised VARC complications in relation to frailty status and these interpretations are 
open to competing risk bias. Therefore, whilst the observations of the effect of frailty on 
early outcomes are important, further work is required in this area. It is in this light that the 
addition of objective frailty measures to ongoing large TAVI registries would be helpful.  
 
Conclusions 
We demonstrate that frailty is associated with poorer early and late outcomes in TAVI 
patients. Objective frailty tools identify an even more vulnerable population at greater than 
double the late mortality risk of non-frail patients. There is currently a lack of consistency in 
frailty measures and clarity in reporting against standardised early VARC outcomes. Given 
the ongoing uncertainty in appropriate patient selection for TAVI, randomised controlled 
trials should consider including patients based on an objective assessment of frailty status. 
Supplementary Data 
This section includes the Medline electronic search strategy, individual study quality (risk of 
bias) assessment, sensitivity meta-analyses for late mortality after TAVI, a comparison of 
predicted against observed early mortality, and a funnel plot for publication bias.  
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Figure 2: Risk of early (≤30 days after TAVI) and late (>30 days) mortality in studies suitable 
for meta-analysis ordered by date of publication. Summary meta-estimate calculations 
based on random effects model analysis. 
 
 








Figure 3: Risk of late (>30 days after TAVI) mortality amongst frail patients. Summary meta-
estimates presented grouped by type of frailty assessment used (subjective vs objective), 
adjustment for confounders (unadjusted vs adjusted) and study quality with regard to frailty 
reporting (high vs low). All summary meta-estimate calculations based on random effects 
model analysis. Individual study level data is presented in Supplementary Figure S1. 
 
 








Table 1: Contextual details of included studies 
 














Fried criteria based on 
gait speed, grip 
strength, weight loss, 
physical activity and 
exhaustion 










ADLs and disability. 
Scored 0-7 with ≥3 
considered frail 






Canada Subjective assessment 
of multidisciplinary 
team 










difficulties with vision 
and polypharmacy) 
SHERPA score (age, 
ADLs, cognitive 
decline, falls and self-
perceived health)  
30 86 53 ISAR: 83.3% 
moderate or 








Femoral 100% - 26.7 








Zahn, 201337 Germany Presumed subjective 
assessment (limited 
detail) 





Puls, 201438 Germany Katz Index of ADLs 
(score <6 frail) 





Germany Subjective assessment 
guided by CHSA Clinical 
Frailty Scale29 score ≥6 
347* 81 52 4.6 - - 24.2 
Capodanno, 
201440 
Italy Geriatric Status Scale 
based upon ADLs, 
cognition, continence 
and mobility. Scored 0-
3 with ≥2 labelled frail 












USA Frailty score composed 
of serum albumin, grip 
strength, gait speed 
and ADLs. Scored 
between 0-12 with ≥6 
considered frail 





Abbreviations: ADLs = activities of daily living. Observed mortality data refer to the whole study population including frail and non-frail individuals.  
*Only the Bonn subgroup that received frailty assessment considered from this multicentre study 
†Only the development cohort of this study included. The validation data set does not contain frailty related outcome data. 
 








Table 2: Early (≤ 30 days) outcomes related to frailty in included studies 
 









30 day MACCE Nil 4.78 0.96 23.77 0.05 
 30 day MAACE (per unit increase in frailty 
index) 
Nil 1.66 1.14 2.44 0.01 
 30 day all cause mortality Nil 8.33 0.99 70.48 0.03 
 30 day all cause mortality (per unit increase in 
frailty index) 
Nil 2.18 1.32 3.61 0.002 
Puls, 201438 All cause mortality Nil 3.05 1.4 5.7 0.003 
 Procedural myocardial infarction Nil 1.08 0.15 7.59 0.94 
 Procedural major stroke Nil 0.98 0.41 2.33 0.95 
 Procedural TIA Nil 1.08 0.07 17.16 0.95 
 Life-threatening or disabling bleeding Nil 0.86 0.45 1.62 0.63 
 Major bleeding Nil 2.17 0.84 5.62 0.11 
 Minor bleeding Nil 1.50 1.05 2.16 0.03 
 Renal failure requiring dialysis Nil 2.01 1.09 3.70 0.02 
Capodanno, 
201440 
All cause mortality Nil 2.09 1.30 3.37 0.003 








Green, 201542 All cause mortality Nil 1.34 0.59 3.04 0.48 
 Cardiovascular mortality Nil 1.22 0.47 3.14 0.68 
 Major stroke Nil 0.61 0.06 6.63 0.68 
 Major bleeding Nil 1.74 0.69 4.42 0.24 
 Major vascular complications Nil 1.42 0.49 4.11 0.52 
 Permanent pacemaker insertion Nil 1.02 0.46 2.26 0.97 
 Renal failure requiring dialysis Nil 1.57 0.60 4.07 0.36 
*Where not presented directly by authors, relative risk ratios calculated from 2 by 2 tables for those with and without frailty. 














Table 3: Late (≥ 30 days) outcomes related to frailty in included studies 
 







Ewe, 201020 MACCE defined as composite of death, 
nonfatal stroke, heart failure or nonfatal 
myocardial infarction (mean follow-up 9.1 
months) 
Logistic EuroSCORE, peripheral vascular 
disease, previous CABG, baseline LVEF 
4.20 2.00 8.84 <0.001 
Stortecky, 
201235 
1 year MACCE Nil 4.89 1.64 14.6 0.003 
 1 year MACCE STS score 4.17 1.37 12.72 0.01 
 1 year MACCE Logistic EuroSCORE 4.48 1.48 13.53 0.01 
 1 year MACCE (per unit increase in frailty 
index) 
Nil 1.80 1.33 2.45 <0.001 
 1 year all cause mortality Nil 3.68 1.21 11.19 0.02 
 1 year all cause mortality STS score 2.93 0.93 9.24 0.07 
 1 year all cause mortality Logistic EuroSCORE 3.29 1.06 10.15 0.04 
 1 year all cause mortality (per unit increase in 
frailty index) 
Nil 1.80 1.31 2.47 <0.001 
Rodes-Cabau, 
201236 
All cause mortality (mean follow-up 42 ± 15 
months) 
Atrial fibrillation, cerebrovascular disease, 
COPD, eGFR, pulmonary hypertension 
1.41 1.02 1.96 0.034 
 Late all-cause mortality (excluding mortality 
within 30 days of TAVI) 
Age, atrial fibrillation, COPD, eGFR 1.52 1.07 2.17 0.021 










1 year all cause mortality (per 1 unit increase 
in SHERPA score) 
Unclear but likely gender, BMI, pulmonary 
hypertension, diabetes 
2.74 1.39 5.39 0.004 
Zahn, 201337 1 year mortality Nil 1.50 1.19 1.89 <0.001 
Puls, 201438 All cause mortality (median follow up 537 
days) 
Age and sex 2.67 1.7 4.3 <0.0001 
Seiffert, 
201439 
1 year mortality Age and sex 1.41 1.23 1.63 <0.001 
Debonnaire, 
201541 
1 year mortality Nil 1.29 0.80 2.06 0.29 
Green, 201542 1 year all cause mortality (frailty 
dichotomised) 
Nil 2.18 1.27 3.75 0.005 
 1 year all cause mortality (frailty 
dichotomised) 
Stepwise inclusion of variables† with 
entry/stay criteria of 0.1/0.1 and a maximum 
of one covariate for every 10 events.  
2.5 1.40 4.35 0.002 
 1 year all cause mortality (per unit increase in 
frailty score) 
Nil 1.12 1.02 1.22 0.01 
 Poor outcome (death or poor quality of life‡) 
at 6 months 
Stepwise inclusion of variables† as above 2.21 1.09 4.46 0.03 
 Poor outcome (death or poor quality of life‡) 
at 1 year 
Stepwise inclusion of variables† as above 2.40 1.14 5.05 0.02 
 
Abbreviations: MACCE = major adverse cardiovascular and cerebral events; CABG = coronary artery bypass grafting; LVEF = left ventricular ejection fraction; COPD = chronic 
obstructive pulmonary disease; eGFR = estimated glomerular filtration rate; BMI = body mass index; TIA = transient ischaemic attack; STS = Society of Thoracic Surgeons. 








*Where not presented directly by authors, relative risk ratios calculated from 2 by 2 tables for those with and without frailty. 
†Candidate variables: age, sex, body mass index, access route, STS score, diabetes, hypertension, angina, heart failure, New York Heart Association class IV, coronary artery 
disease, previous coronary angioplasty, previous CABG, cerebrovascular disease, peripheral vascular disease, previous balloon aortic valvuloplasty, permanent pacemaker, 
renal disease, liver disease, chronic pulmonary disease, aortic valve mean gradient, ejection fraction, moderate or severe mitral regurgitation. 












Table 4: Comparisons of mortality in frail and non-frail patients after TAVI 
 











Frail (n) 233 144 306 98 110 891 
Frail deaths (n) 70 80 30 20 36 236 
Non-frail (n) 1085 156 950 413 134 2738 
Non-frail deaths (n) 217 37 47 60 21 382 









Frail years of follow-
up 
250 212 25 98 110 695 
Non-frail years of 
follow-up 
1166 230 78 413 134 2021 
Death rate/100 frail 
patient years 
28 38 120 20 33 34 
Death rate/100 non-
frail patient years 
19 16 60 15 16 19 
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